DexCom's Glucose Monitoring System Snags Breakthrough Device Tag For Hospital Use

The FDA granted Breakthrough Device Designation for DexCom Inc DXCM for continuous glucose monitoring (CGM) use in the hospital setting.

  • Dexcom CGM uses a small, wearable sensor and transmitter to continuously measure and send glucose levels wirelessly to a smart device, providing real-time glucose data without the need for fingersticks. 
  • The system also offers customizable alerts and alarms to help avoid potentially dangerous low and high blood sugar events.
  • Related: DexCom Stock Falls As Q4 Profit, FY22 Sales Outlook Trail Wall Street Estimates.
  • "During the COVID-19 pandemic, the FDA allowed Dexcom CGM to be used in hospitals to help health care providers manage patient glucose levels," said Gil Rivas, vice president, general manager of a hospital at Dexcom. "What started as a response during the pandemic has shown promise as a better alternative to fingerstick blood glucose tests with a greater quality of care and patient satisfaction."
  • Price Action: DXCM shares closed 1.33% lower at $408.41 on Tuesday.
Loading...
Loading...
DXCM Logo
DXCMDexCom Inc
$85.801.11%

Stock Score Locked: Edge Members Only

Benzinga Rankings give you vital metrics on any stock – anytime.

Unlock Rankings
Edge Rankings
Momentum
32.77
Growth
74.07
Quality
11.67
Value
15.30
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Comments
Loading...